The “Global Chronic Kidney Disease Drugs Market” will grow at a CAGR of 4.1% during the forecast period. http://bit.ly/2PcH3cB Get free sample report at http://bit.ly/2GhGR7Q
2. Infoholic Research (https://www.infoholicresearch.com/)is a global market research and
consulting organization providing strategic and high-level market intelligence in emerging and
niche markets in Healthcare, ICT, Semiconductors, Chemicals & Materials domain. We aim at
delivering high-quality results to our clients providing them with in-depth industry insights to
identify new business opportunities and nurture their business strategies.
Our team of analysts spanning verticals such as ICT, Healthcare, Chemicals and Semiconductors
creates extensive Market Research reports every month covering market trends and dynamics
envisioning the road ahead.
We also have a Newsletter wherein we keep on featuring guest columns from domain experts,
tête-à-tête with leaders and likewise. Additionally, our insightful blogs and articles truly keep the
readers hooked.
You may also send in your requests for getting our analysts’ viewpoints in specific areas of
Healthcare, ICT, Chemicals & Materials, and Semiconductors to validate a certain market trend/
insight or finding.
Please let me know how we both can create a cohesive quotient and associate for creating a win-
win situation for both of us.
About Us
3. Market Snapshot
Page 1
Increasing CKD incidence, aging population, promising repayment or
reimbursement plans, and increasing investments in R&D activities for the CKD
drug development are the major factors driving the market growth.
The high unmet needs have made the market players to focus on
modernization and technical developments for the treatment, which is likely to
enhance the growth of the market globally.
Nevertheless, complex drug development process and competition from
biosimilars due to loss of patents have hindered the market growth.
Cell therapy produces better results in the earlier stages of kidney disease and
has been shown to eliminate or reduce the need for regular dialysis.
Currently, The Harvard Stem Cell Institute is evolving new remedies to
restore kidney impairment, dropping the necessity for dialysis and
transplantation.
Research is being done to study the potential of miRNA as effective biomarkers
and therapeutic targets for CKD treatments.
Click Here To Access Full Report Summary
4. Scope of the Report
Page 2
The report provides details about the chronic kidney disease drugs market.
The market is analyzed by:
Drug Class Type – Antihypertensives, Antihyperlipidemics, Erythropoiesis-
stimulating Agents (ESAs), Diuretics, and Others
End-users – Hospitals and Specialty Clinics
Regions – North America, Europe, Asia Pacific, and Rest of the World
The report covers drivers, restraints, and opportunities (DRO) affecting the
market growth over the next forecast years (2019–2025).
It also contains an analysis of vendors, which includes financial health,
business units, key business priorities, SWOT, and business strategies.
The report covers competitive landscape, which includes mergers &
acquisitions, joint ventures & collaborations, and competitor comparison
analysis.
In the vendors profile section, for the companies that are privately held,
financial information and revenue of segments will be limited.
Click Here To Access Full Report Summary
5. Market
Characteristics
Page 3
Drivers
High incidence of chronic kidney disease (CKD)
Rise in the incidence of cardiovascular disorders
and diabetes
Increase in the global geriatric population
Restraints
o Competition from biosimilars
o Complex drug development process
Opportunities
Promising chronic kidney disease drug pipeline
Market expansion opportunities in emerging nations
Novel therapeutic approaches such as cell therapy
Download Sample Report
6. Page 4
Regions: Market Size and Analysis
$4,651 Mn
Americas
Download Sample Report
1,761.1
0 XX XX XX XX XX XX XX
Rest of the World
Asia Pacific
Europe
North America
2025 2018
7. Competitive Landscape
Page 5
The chronic kidney diseases drugs market is growing at a flat rate,
with a single-digit CAGR during the forecast period. High incidence
of chronic kidney disease (CKD), rise in the incidence of
cardiovascular disorders & diabetes, and increase in the global
geriatric population are few of the factors driving the market
growth. Various initiatives are taken by government
establishments and market players to increase awareness.
Campaigns are conducted globally to encourage people to adopt
healthy lifestyles. For instance, the Government of India ruled out
a National Dialysis Program under National Health mission, which
was an initiative of Ministry of Health and Family Welfare in 2016
to provide significant life-saving process near to the public and
also for dropping disadvantage on account of out of pocket
expenses for patients. In May 2018, the American Kidney Fund
(AKF) launched complete innovative kidney disease education
portal.
However, the competition from biosimilars and complex drug
development process are hampering the market growth. In
addition, increase in the death toll and increase in the medical
treating cost have increased the burden on the individual and the
community.
Download Sample Report
9. Table of Content
Page 7
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic
Research
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Active Pharmaceutical Ingredients
3.4.2 Over-the-Counter Drugs
3.4.3 Human Insulin
4 Market Outlook
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
4.3 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 High incidence of chronic kidney
disease (CKD)
5.1.1.2 Rise in the incidence of
cardiovascular disorders and
diabetes
5.1.1.3 Increase in the global geriatric
population
5.1.2 Restraints
5.1.2.1 Competition from biosimilars
5.1.2.2 Complex drug development process
5.1.3 Opportunities
5.1.3.1 Promising chronic kidney disease
drug pipeline
5.1.3.2 Market expansion opportunities in
emerging nations
5.1.3.3 Novel therapeutic approaches such
as cell therapy
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and
Analysis
6.1 Overview
6.2 Antihypertensives
6.3 Antihyperlipidemics
6.4 Erythropoiesis-stimulating Agents
6.5 Diuretic Drugs
6.6 Others
7 End-users: Market Size and
Analysis
7.1 Overview
7.2 Hospitals
7.3 Specialty Clinics
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 Overview
8.3 Europe
8.3.1 Overview
8.4 Asia Pacific
8.4.1 Overview
8.5 Rest of the World
8.5.1 Overview
9 Competitive Landscape
10 Vendors Profile
10.1 AbbVie Inc.
10.1.1 Overview
10.1.2 Geographic Revenue
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Amgen Inc.
10.2.1 Overview
10.2.2 Geographic Revenue
10.2.3 Business Focus
10.2.4 SWOT Analysis
10.2.5 Business Strategie
10.3 GlaxoSmithKline plc
10.3.1 Overview
10.3.2 Business Units
10.3.3 Geographic Revenue
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Revenue
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 AstraZeneca PLC
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategies
11 Companies to Watch for
11.1 Pfizer Inc.
11.1.1 Overview
11.2 Sanofi
11.2.1 Overview
11.3 Teva Pharmaceutical Industries
Ltd.
11.3.1 Overview
11.4 Johnson & Johnson
11.4.1 Overview
11.5 Keryx Biopharmaceuticals Inc.
11.5.1 Overview
11.6 FibroGen Inc.
11.6.1 Overview
Annexure
Abbreviation
Download Sample Report
10. Assumptions
Page 8
• The global economic scenario is expected to be on a positive
side over the forecast period, i.e., from 2019 to 2025.
• The exchange rates used are taken from Oanda.com (average
of 365 days) throughout the report for key market numbers.
• The financial aspects shown in the report are as per the
annual reports available in the public domain.
• The company’s employee count and year of establishment are
taken from the public domain which may differ from the actual
employee count.
• Active pharmaceutical ingredients, over-the-counter drugs,
and anti-diabetic therapies are considered as related markets.
• CAGR is calculated from 2019 to 2025 with 2018 as the base
year.
• The calendar year is followed (January–December).
• US Dollar ($) is considered for the calculation of the market.
Click Here To Access Full Report Summary
11. Get In Touch
+91 804 615 1400 inquiry@infoholicresearch.com
sales@infoholicresearch.com
Infoholic Research LLP
No.45/1, Residency Road Cross,
5th Floor, Leo Shopping Complex, Bengaluru – 560025, India
Buy Report @
https://www.infoholicresearch.com/report/chronic-kidney-
disease-drugs-market